Kartesada (Pregabalin)

Pregabalin binds to the α2‑δ subunit of voltage‑gated calcium channels in the central nervous system. This binding limits calcium entry into presynaptic neurons, decreasing the release of excitatory neurotransmitters such as glutamate, norepinephrine, and substance P, which underlies its anticonvulsant, analgesic, and anxiolytic actions.

The appropriate dose of Kartesada is individualized by the prescribing healthcare professional based on the specific indication, patient age, renal function, and response to therapy. No fixed regimen is provided here; clinicians adjust dosing to achieve optimal therapeutic effect while minimizing adverse reactions.

Safety data for pregabalin in pregnancy and lactation are limited, and the product carries an unknown pregnancy category. It should only be used when the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by a qualified prescriber.

To request Kartesada, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Both pregabalin (Kartesada) and gabapentin belong to the gabapentinoid class and share a similar mechanism of binding to the α2‑δ calcium‑channel subunit. Pregabalin generally has higher bioavailability and a more predictable pharmacokinetic profile, allowing for simpler dosing schedules, whereas gabapentin may require more frequent dosing.

Kartesada should be stored at ambient temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the container tightly closed and out of reach of children. Do not store in bathrooms or near heat sources.

Kartesada is taken orally, usually with a glass of water. The tablet should be swallowed whole and not chewed or crushed unless specifically instructed by a healthcare professional. Administration can be with or without food, depending on the prescriber’s guidance.

Serious risks include angioedema (swelling of the face, lips, tongue, or throat) and the emergence of suicidal thoughts or behaviors. Patients should be monitored closely for signs of severe allergic reactions or mood changes, and any concerning symptoms should prompt immediate medical evaluation.

Kartesada is contraindicated in patients with known hypersensitivity to pregabalin or any of the tablet’s excipients. Caution is also advised for individuals with severe renal impairment, uncontrolled heart failure, or a history of substance misuse, as these conditions may increase the risk of adverse effects.